Comparative Pharmacology
Head-to-head clinical analysis: CIPRODEX versus CORDRAN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRODEX versus CORDRAN N.
CIPRODEX vs CORDRAN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking bacterial DNA replication; dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension: 4 drops into affected ear(s) twice daily for 7 days.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
None Documented
None Documented
Ciprofloxacin: terminal elimination half-life 3-5 hours (prolonged to 5-10 hours in renal impairment). Dexamethasone: biological half-life 36-54 hours.
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
Ciprofloxacin: 50-70% renal (glomerular filtration and tubular secretion), 20-35% biliary/fecal. Dexamethasone: renal elimination of metabolites, <5% unchanged.
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Category C
Category C
Antibiotic/Corticosteroid Combination (Otic)
Topical Corticosteroid + Antibiotic